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Purpose: To investigate the expression of Aurora Kinase A and B in patients with chondrosarcoma and consider it
as a prognostic marker and molecular target of therapy.
Methods: To evaluate the relationship of the Aurora Kinase A and B and the clinical pathological parameters and
prognosis of chondrosarcoma. 72 case chondrosarcoma and 42 case chondroma were performed
immunohistochemistry on the tissue microarray paraffin sections. The survival time of patients was followed-up.
Results: The expression of Aurora Kinase A and B in chondrosarcoma was significantly higher than that in
chondroma (p<0.01). There were differences about the expression of Aurora Kinase A and B in chondrosarcoma
between the recurrence group and the non-recurrence group, metastatic group and non-metastatic group
(p<0.05), but not age and gender (p>0.05). The expression of Aurora Kinase A and B were significantly lower in
group low grade conventional chondrosarcoma than that in groups medium and high grade conventional
chondrosarcoma (p<0.01). The expression of Aurora Kinase A and B in chondrosarcoma showed a positive
correlation (p<0.01). According to the Kaplan Meier analysis and multivariate Cox regression analysis, the survival
rate was significantly different between the patients with positive Aurora Kinase A and the patients with negative
expression (p<0.05) and Aurora Kinase A expression was an independent risk marker of survival(HR=11.263, 95%CI:
2.317–54.748, P=0.003).
Conclusion: Both the Aurora Kinase A and B might involve in the oncogenic, invasive and metastatic process of
chondrosarcoma; however, the mechanism is still unclear. The Aurora Kinase A and B could be used as a new
prognostic marker and molecular therapeutic target for chondrosarcoma.
Virtual Slide: The virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/
vs/9101494267377096.
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Chondrosarcoma is the second most common malignant
bone tumors following the osteosarcoma in China [1], in
which the tumor cells can generate a lot of bone matrix.
To some extent, the chondrosarcoma is not sensitive to
chemotherapy and radiation therapy, due to its charac-
teristic of increase of extracellular matrix, decrease of* Correspondence: happy_liangxiaohui@163.com
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reproduction in any medium, provided the ordivided cells vessels. To date, the dominant clinical treat-
ment for chondrosarcoma is surgical resection; however,
the recurrence rate is too high (20%). Therefore, there is
an urgent need of a new therapy for patients with chon-
drosarcoma, especially for patients with recurrence.
Aurora Kinase family is a newly discovered serine and
threonine kinase family, which regulates the function of
centriole and microtubule, and plays an important role
in maintaining the normal mitosis and cell cycle. How-
ever, the disordered expression of Aurora Kinase pro-
moted the oncogenesis. The Aurora Kinase family
consists of 3 members in mammal: Aurora Kinase A, Btd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.






















average median survival time 46(month)
average follow-up interval 39.4(month)
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http://www.diagnosticpathology.org/content/7/1/84and C. In recent study, it showed that tumorigenesis
appeared by transfection of the Aurora Kinase A gene
into 3T3 cells in nude mouse [2], and the Aurora Kinase
A gene had been identified as a new oncogene. Aurora
Kinase A gene was highly expressed in various malignant
tumors, such as oophoroma, colorectal cancer and acute
myeloid leukemia [3-5]. Aurora Kinase B was also highly
expressed in many tumor tissues, including oral cancer,
the non-small-cell lung carcinoma and hepatocellular
carcinoma [6-8], etc. Furthermore, it has been showed
that the activity inhibitors of Aurora Kinase could inhibit
the growth of cancer cells, and some inhibitors have
been applied in the pre-clinical experimental stage
[9,10].
Whether the Aurora Kinase A and B were expressed
in the chondrosarcoma is still unknown, in this study,
we investigated the expression of the Aurora Kinase A
and B in the chondrosarcoma tissues by immunohisto-
chemistry and analyzed its clinical significance; and we
also followed-up the patients.
Materials and methods
Tissue samples
72 chondrosarcoma samples and 42 chondroma samples
were randomly chosen from the Department of Path-
ology in Qilu Hospital of Shandong University from
January 2005 to June 2011, all samples were fixed with
10% formaldehyde and embedded with paraffin. Mean-
while, follow-up survey was conducted by telephone.
The clinical parameters included the age, gender, patho-
logical type and the status of recurrence, metastasis and
invasion, as shown in Table 1. Informed consent was
obtained from all of the patients.
Tissue microarray (TMA)
Firstly, all samples were performed hematoxylin and
eosin staining (HE), then two fields were chosen from all
HE slides and the corresponding spots were marked on
the surface of the paraffin block. Next the marked areas
were punched out and placed into the recipient block
side by side with the tissue microarray punching instru-
ment. Each tissue point was 2 mm in diameter and
assigned with a unique tissue microarray location num-
ber, which was linked to a database containing other
clinicopathologic data.
Immunohistochemistry assay
The streptavidin-peroxidase-biotin (SP) immunohisto-
chemical method was used to study the expression of
Aurora Kinase A and B in the tissue microarrays. The
paraffin specimens were cut into 4 μm sections and
stayed at 60°C for 60 min. Then the sections were
dewaxed and rehydrated. Next, antigen retrieval was
achieved by microwave using EDTA buffer for 2.5 minand then cooled at room temperature for 30 min. After
washing with PBS for 3 times, the endogenous peroxid-
ase was blocked with 3% hydrogen peroxide, followed by
incubation with goat serum to block nonspecific binding.
Then rabbit anti-human polyclonal Aurora-A antibody
(1:800; ABGENT,American) and rabbit anti-human poly-
clonal Aurora-B antibody (1:1000; ABGENT,American)
were incubated with the sections overnight at 4°C. After
washing, the tissue sections were treated with biotiny-
lated anti-rabbit secondary antibody (Zhongshan Bio-
technology Company, Beijing, China) for 30 min; then
incubated with streptavidin-horseradish peroxidase com-
plex for 20 min. At last, the sections were developed
with diaminobenzidine (DAB) and counterstained with
hematoxylin. For negative controls, the Aurora-A anti-
bodies and the Aurora-B antibodies were replaced by
PBS.
Evaluation of immunohistochemical staining
3 visual fields (400×) were randomly chosen and cells
were counted with Image-Pro Plus (Media Cybernetics,
Bethesda, MD). The Aurora Kinase A is expressed in
cytoplasm and the Aurora Kinase B is expressed in both
cytoplasm and nucleus. Grade and score by the intensity
of staining: 0 point for colorless, 1 point for light yellow,
2 points for claybank and 3 points for brown; then grade
by the ratio of positive cell: 0 point for no positive
Figure 1 Expression of Aurora Kinase A and B testing by Immunohistochemistry method (×400). A. the positive expression of Aurora
Kinase A in chondrosarcoma B. the negative expression of Aurora Kinase A in chondroma C. the positive expression of Aurora Kinase B in
chondrosarcoma D. the negative expression of Aurora Kinase B in chondroma.
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http://www.diagnosticpathology.org/content/7/1/84staining cells, 1 point for positive ratio ≤10%, 2 points
for 11%–50%, 3 points for 51%–75% and 4 points
for>75%. At last multiply the 2 score system: ≤3 points for
negative, >3 points for positive. The slides were reviewed
and scored independently by two observers who blinded to
the patients’ information.
Statistical analysis
Data were analyzed by SPSS17.0 statistical analysis soft-
ware. A P<0.05 was considered statistically significant.
Results
Expression of Aurora Kinase A and B in chondrosarcoma
and chondroma
The Aurora Kinase A protein was observed mainly in
the cytoplasm (Figure 1A), and it was positive in 45 of
the 72 patients (62.5%) with chondrosarcoma and in 6 of
the 42 cases (14.3%) with chondroma (Table 2). The
positive ratio of Aurora Kinase A was significantly
higher in chondrosarcoma than that in chondroma tis-
sues (p<0.01) (Figure 2). The Aurora Kinase B protein
was detected in both the nucleus and the cytoplasm
(Figure 1C). The positive ratio of Aurora Kinase B wasTable 2 Expression of Aurora Kinase A and B in the tissue of
Group Chondrosarcoma
Aurora Kinase A positive 45
Aurora KinaseA negative 27
Aurora KinaseB positive 47
Aurora KinaseB negative 2565.3% (47/72) in the chondrosarcoma and 19% (8/42) in
the chondroma tissues (Table 2). The positive ratio of
Aurora Kinase B was significantly higher in the chondro-
sarcoma than that in chondroma tissues (p<0.01)
(Figure 2).
Expression of Aurora Kinase A and B and chondrosarcoma
The ratio of positive expression of the Aurora Kinase A
was 33.3%and 92.9% inIandII-III stage of the conven-
tional chondrosarcoma, respectively (p<0.01); the more
malignant tumor, the higher expression of the Aurora
Kinase A. The ratio of positive expression was 90% and
51.9% in the group with and without recurrence, re-
spectively (p<0.05). The ratio of positive expression was
83.3% and 52.1% in the metastatic and non-metastatic
group, respectively (p<0.05). However, the expression of
Aurora Kinase A was not correlated with age, gender
(p>0.05) (Table 3).
The ratio of positive expression of Aurora Kinase B
protein in common chondrosarcoma groupIandII-III
was 33.3% and 100% respectively (p<0.01); which means
the more malignant tumor, the higher expression of the






Figure 2 Comparison of the expression rate of Aurora Kinase A and B in chondrosarcoma and chondroma.
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recurrence group, respectively (p<0.05). The expression
of Aurora Kinase B was not correlated with age, gender
too. The expression of Aurora Kinase A was positively
correlated with the expression of Aurora Kinase B
(p<0.01) (Table. 4). The Aurora Kinase A and B were
negative in negative controls.Survival analysis
The survival time of the patients was followed-up and
analyzed with the Kaplan-Meier survival analysis and
multivariate Cox regression analysis method. The aver-
age follow-up interval was 39.4 months and the average
median survival time was 46 months. The results of
Kaplan-Meier survival analysis showed that chondrosar-
coma patients who had a positively expressed Aurora
Kinase A had a relatively poor prognosis (p<0.05)
(Figure 3) which indicates that the Aurora Kinase A
might be a prognostic marker for the chondrosarcoma.Table 3 Association of Aurora Kinase A,B expression with the
Clinicopathological parameters N Aurora Kinase A χ2
positive negative
Age(year)
<50 49 32 17 0.5
≥50 23 13 10
Gender
male 35 20 15 0.8
female 37 25 12
Recurrence
positive 20 18 2 7.3
negative 52 27 25
Metastatic
positive 24 20 4 5.4
negative 48 25 23
Conventional type
I 27 9 18 10
II-III 14 13 1
*using continuity correction Chi-Square.The results of multivariate Cox regression analysis showed
that Aurora Kinase A was an independent risk marker
of overall survival(HR=11.263, 95%CI: 2.317–54.748,
P=0.003) (Table 5), However, there was no significant
relationship between Aurora Kinase B and the survival
time of the patients with chondrosarcoma (p>0.05).
Aurora Kinase B was not an independent risk marker
of overall survival (HR=0.246, 95%CI: 0.070–0.869,
P=0.029).Discussion
Tumor is a type of general, systematic and step-by-step
developing disease involving lots of factors; it is caused
by the mutation of the oncogenes and disorders of some
genes [11]. Chondrosarcoma derived from the chondro-
cytes, which is a primary malignant tumor, which con-
sists of the tumorous chondrocytes and cartilage matrix.
The prevalence of chondrosarcoma was approximately
20% of all the primary bone malignant tumors [12]. Atclinicopathological features of the chondrosarcoma
value P value Aurora Kinase B χ2value P value
positive negative
15 0.473 29 20 2.513 0.113
18 5
3 0.361 22 13 0.176 0.675
25 12
85* 0.007 17 3 3.624* 0.047
30 22
* 0.020 21 3 6.442* 0.011
26 22
.85* 0.001 9 18 14.04* 0.000
14 0
Table 4 Correlation of the expression of Aurora Kinase A
and B in chondrosarcoma
Aurora Kinase A Aurora Kinase B χ2 value P value
+ -
+ 40 5 28.277 0.000
- 7 19
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http://www.diagnosticpathology.org/content/7/1/84present, the research on molecular targeted therapy for
malignant tumors is popular all over the world. The mo-
lecular targeted therapy mainly corrects the abnormal
signaling pathways of the tumor, with the characteristics
of high selectivity, hypotoxicity and high therapeutic
index [11]. The abnormal expression of Aurora Kinase
family is closely associated with the development of
tumor, because of the crucial role of Aurora Kinase fam-
ily plays in the mitosis and cell cycle. In this report, we
investigated the expression of Aurora Kinase A and B in
chondrosarcoma and provided a strong support for the
development of the new drugs of molecular targeted
therapy for chondrosarcoma.
Aurora Kinase A is a member of Aurora Kinase family
which has been considered as a crucial factor to regulate
mitosis. It participates in the maturation and segregation
of centriole, the assembly and stabilization of spindle,
the condensation of chromosome and the converging
and stabilization of the median plate, etc. However, its
overexpression can result in the augmentation of centri-
ole, the formation of multiploid and the loss of p53.
Through studying the expression profile of Aurora Kin-
ase A in various normal tissues, we found that Aurora
Kinase A mRNA only had a relative low expression level
in thymus, but was barely detected in other tissues, suchFigure 3 The Kaplan-Meier survival analysis of 72 patients with chond
that patients with chondrosarcoma negative for Aurora Kinase A had highe
expression of Aurora Kinase B shows no significant relationship with the ovas the brain, lung, intestine, spleen and testis. In various
malignant tumors Aurora Kinase A had been found
overexpression. Marco et al. reported that the expression
of Aurora Kinase A was up-regulated in hepatoma espe-
cially in the type of poorly differentiated tissues [13].
Rudolf et al. reported that the expression of Aurora
Kinase A mRNA was up-regulated in the head and neck
carcinoma [14]. Therefore, it could be considered as a
prognostic factor for malignant tumors.
Our results showed that the expression of Aurora
Kinase A was very low in chondroma tissues, while it
was strongly expressed in chondrosarcoma; which indi-
cated that Aurora Kinase A played an important role in
the initial and developmental stage of the chondrosar-
coma. The results also showed that the expression of
Aurora Kinase A was significant different between the
recurrence group and the non-recurrence group, the
metastatic group and non-metastatic group, suggesting
that the high expression of Aurora kinase A is associated
with oncogenesis and the grade of the malignancy and
differentiation of chondrosarcoma. However, there was
no correlation of the expression of Aurora Kinase A and
the age, gender, the site and size of the tumor. Combin-
ation of immunohistochemisty and follow-up data we
can see that there was significant difference of the over-
all survival rate between the Aurora Kinase A positively
expressed group and the negatively expressed group.
In addition, it has been reported that the high expres-
sion of Aurora Kinase A in esophageal squamous cell
carcinoma could significantly promote the proliferation
of tumor cells and increase the resistance to apoptosis
induced by DDP and ultraviolet radiation [15]. Takayuki
et al. reported that Aurora Kinase inhibitor ZM447439rosarcoma. A: The analysis with Kaplan-Meier method clearly showed
r overall survival rates than those positive for Aurora Kinase A. B: The
erall survival rates of the patients with chondrosarcoma.
Table 5 Multivariate Cox regression analysis of Aurora
Kinase A and B and clinicopathological features
Category Hazard Ratio P-value 95.0%CI for HR
Lower Upper
Gender Male/Female 1.033 0.945 0.409 2.609
Age <50/≥50 2.370 2.370 0.764 7.351
Recurrence No/Yes 0.464 0.120 0.176 1.221
Metastatic No/Yes 1.088 0.879 0.365 3.249
Aurora Kinase A +/− 11.263 0.003 2.317 54.748
Aurora Kinase B +/− 0.246 0.029 0.070 0.869
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http://www.diagnosticpathology.org/content/7/1/84could inhibit the growth of leukemia cells [5]. Therefor-
ethe inhibition of the activity of Aurora Kinase A could
lead to the tumor cell apoptosis instead of malignant
proliferation. Accordingly, Aurora Kinase A is expected
to become the new target for chondrosarcoma. In the
further study, we will further conduct related experi-
ments to identify whether the Aurora Kinase A inhibitor
can be used as the molecular target treatment for
chondrosarcoma.
The Aurora Kinase B is the component of the
chromosome passenger protein complex which partici-
pate in the chromosome condensation, spindle assembly,
segregation of sister chromatids and cytocinesis. Recent
studies reported that Aurora Kinase B expressed abnor-
mally in various malignant tumors, such as breast cancer
[16] and acute lymphatic leukemia [17]. Our results
showed that in chondroma tissues the expression of
Aurora Kinase B was barely detected, however, most of
the chondrosarcoma tissue cells expressed positively,
even 100% positive in stage III.It indicated that Aurora
Kinase B played an important role in the process of the
oncogenesis and development of chondrosarcoma.
Moreover, we found the positive expression of Aurora
Kinase B was significant different between the metastatic
group and non-metastatic group and the recurrence
group and the non-recurrence group, which suggests
that Aurora Kinase B impacts on the invasiveness of
chondrosarcoma. Ren et al. reported that it might en-
hance the sensitivity of ovarian cancer cell A2780 against
chemotherapy to paclitaxel and increase the apoptosis
by application of AURKB siRNA to A2780, indicating
that inhibit of Aurora Kinase B could finally restrain the
neoplastic growth by inducing apoptosis of tumor cells
[18]. A variety of Aurora Kinase inhibitors have been
developed, such as hesperetin against Aurora Kinase B,
quinazoline against Aurora Kinase A and B simultan-
eously and vX-680 against Aurora Kinase A, B and C;
besides, some inhibitors have been applied in pre-
clinical and I,II stage clinical trials [19]. In the future,
our group will study whether Aurora Kinase B inhibitors
can inhibit the growth and proliferation of chondrosar-
coma cells in vitro and in vivo. Dual inhibitors may be abetter choice due to the consistent expression of Aurora
Kinase A and Aurora Kinase B.
Conclusion
Our study found that the expression of Aurora Kinase A
and B was significantly up-regulated in chondrosarcoma,
and the expression of Aurora Kinase A and B was corre-
lated with the recurrence and metastasis of chondrosar-
coma. Which demonstrate that Aurora Kinase A and B
play an important role in the formation and develop-
ment of chondrosarcoma. In addition, survival analysis
and multivariate Cox regression analysis showed that
Aurora Kinase A also affected patients’ outcome. There-
fore, Aurora kinase A can be used to predict the progno-
sis of patients with chondrosarcoma.
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